Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments ...

In trading on Wednesday, shares of Structure Therapeutics Inc (Symbol: GPCR) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $19.61 per share.